Published September, 2009
By Zahid H. Siddik
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

This loss may occur through aberration in any single component involved in signal transduction pathways that orchestrate checkpoint regulation, which may manifest through either a failure to activate the checkpoint or a failure to respond to the activated checkpoint.

---

Published July, 2009
By Erwin G. van Meir
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

Their joint efforts are gradually peeling away the mysteries surrounding the genesis and progression of these tumors and inroads are being steadily made into understanding why they resist therapies.

---

Published May, 2009
By Amy M. Fulton and Amy Fulton
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

Chemokines are a superfamily of low molecular weight cytokines. In humans, there are approximately 45 chemokines that bind to 19 G-protein-coupled receptors. This book reviews what we do and do not know about the role of chemokine receptors in cancer behavior.

---

Published May, 2009
By Beverly A. Teicher and Rebecca G. Bagley
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

Significance of Stem Cells to Tumor Development Cancer stem cells remain a controversial topic and the criteria that define cancer stem cells are continuing to evolve.

---

Published February, 2009
By Keiko Hiyama
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

Until now, there are several good books on telomere and telomerase focusing on biology in ciliates, yeasts, and mouse or basic sciences in human, providing basic scientists or students with updated knowledge.

---

Published December, 2008
By Franco Muggia, Bonetti, Andrea Bonetti, Roberto Leone and Stephen B Howell
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

Cisplatin is still an irreplaceable component of a regimen that produces high cure rates in even advanced nonseminomatous germ-cell cancers, and is widely used in the treatment of ovarian cancers and other gynecologic cancers, head and neck, and numerous other tumor types.

---

Published December, 2008
By Gavin J. Gordon
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

This book shows how a bioinformatics approach has been used to characterize various cancer-related processes. It provides a historical and technical perspective on the analytical techniques, methodologies, and platforms used in bioinformatics experiments.

---

Published November, 2008
By David S. Ettinger
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

In this volume, Supportive Care in Cancer Therapy, a part of the Cancer Drug Discovery and Development series, the contributors provide an up-to-date, concise review of specific consequences of cancer and its treatment.

---

Published October, 2008
By Federico Innocenti
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response provides the most comprehensive body of knowledge available on the role of genetic and genomic variation in the individualization of drug therapies in cancer patients.

---

Published September, 2008
By John D. Haley and William John Gullick
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

The epidermal gro wth factor (EGF ) receptor and its downstream signal transduction networks have been implicated in the ontology and maintenance of tumor tissues, which has motivated the discovery and development of molecularly targeted anti-EGF receptor therapies.

---